Compare Revvity Inc (RVTY) vs Banco Santander SA (SAN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Revvity Inc vs Banco Santander SA — how do they compare? Revvity Inc trades at $154.1 (market cap $16.98B), while Banco Santander SA trades at $13.5 (market cap $192.86B). The key difference: Banco Santander SA is far larger — about 11.4× Revvity Inc's market cap, and Banco Santander SA pays the higher dividend (2.06%). Which is the better fit depends on your goals — on Pluang, investors hold Revvity Inc for 12 Days and Banco Santander SA for 55 Days on average.
| RVTY | SAN | |
|---|---|---|
Market Cap | $16.98B | $192.86B |
Volume | 1,456,900 | 10,644,519 |
Sector | Health | Financials |
52-Week High | $157.36 | $15.05 |
52-Week Low | $82.26 | $9.65 |
Typical Hold Time | 12 Days | 55 Days |
Enterprise Value | $19.30B | $360.86B |
Dividend Yield | 0.18% | 2.06% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RVTY trades at $155.01, up 0.92% with a bullish technical outlook. The stock shows strong earnings momentum with three consecutive quarterly beats and maintains solid profitability with 54.98% gross margins. Recent developments include new product launches in Europe and strategic acquisitions to expand metabolic disease research capabilities.
The investment case balances premium valuation (P/E 73.15) against consistent execution and growth initiatives. Key risks include China market pressures and margin compression, while analyst consensus remains positive with 52% buy ratings. Upside potential exists if Q3 earnings meet expectations in November.
Banco Santander (SAN) trades at $13.49, down 1.24% with bearish technical signals, though fundamentals show strength with 26.25% net margins and 16.07% ROE. Recent earnings show mixed quarterly performance, beating in Q1 but missing in Q2. The company completed the Webster Bank acquisition in August 2026, expanding U.S. presence and driving record profits. Cash flow trends remain negative, but revenue and net income have grown steadily from 2022-2026.
Outlook remains cautiously optimistic with 64% analyst buy ratings supporting growth potential from strategic acquisitions and digital transformation. Key risks include negative cash flow trends, high debt levels at $288B, and economic sensitivity. The stock offers value at 13.55 P/E but requires monitoring of operational cash flow recovery and integration of recent acquisitions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Revvity Inc
Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →About Banco Santander SA
Santander's focus is on retail and commercial banking. Latin America is geographically the largest operation, with Brazil by far the largest. Its continental European business is still mainly Iberian. Santander's U.K. presence is the result of the acquisition of building society Abbey. In the U.S., Santander operates a vehicle finance business and a regional bank focused on the Northeastern states.
Read more on SAN →
